Nutt et al - Figure 1

Sep 04, 2014

30 likes | 173 Views

B. A. Nutt et al - Figure 1. Nutt et al - Figure 2. A. B. Nutt et al - Figure 3.

Share Presentation

Embed Code

Link

nutt
al figure 1
al figure 2

lavender

Download Presentation

Nutt et al - Figure 1

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

B A Nutt et al - Figure 1
Nutt et al - Figure 2
A B Nutt et al - Figure 3

Pöschl et al., Suppl. Figure 1

Pöschl et al., Suppl. Figure 1. a. Math1-cre::SmoM2 Fl/+ Ctnnb1(ex3) Fl/+. Math1-cre. Math1-cre::SmoM2 Fl/+. P0. EGL. IGL. EGL. P2. ML. PL. IGL. EGL. P7. ML. PL. IGL. b. Math1-cre::SmoM2 Fl/+ Ctnnb1(ex3) Fl/+. Math1-cre. Math1-cre::SmoM2 Fl/+. H&E. P16. Ki67. Ki67. Ki67.

179 views • 3 slides

Rafehi et. al., Supplementary Figure 1

B. Rafehi et. al., Supplementary Figure 1. A. C. Rafehi et. al., Supplementary Figure 2. Rafehi et. al., Supplementary Figure 3. Keratinocytes (20 µM). K562 (100 µM).

142 views • 3 slides

Lane et al. Supp Figure 1

Lane et al. Supp Figure 1.

144 views • 1 slides

Supplementary Figure 1 Lewis, et al.

Cell Death (Ramos). Untreated. Proliferation (Ramos). hIgG (crosslinked). Dacetuzumab (soluble). Dacetuzumab (crosslinked). Percent Cell Death (apoptotic + necrotic). Crosslinking Ab. Dacetuzumab (soluble). hIgG (crosslinked). Dacetuzumab (crosslinked). CD40 Ligand.

103 views • 1 slides

Andrade et al. - Supplementary Figure 1

Andrade et al. - Supplementary Figure 1. A. 10 20 30 40 50 60 70 80 90 100 ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|

100 views • 1 slides

Farmer et al Supplementary Figure 1

Farmer et al Supplementary Figure 1. [ KU0058684] (  M). 1. 2. 0. 1. 0. 0. IC 50 = 1nM. 0.00001. 0.0001. KU0051529 PARP-1 IC 50 = 730nM. 0.001. 0.01. 8. 0. 0.1. 100. 10. 0. 1. % activity. 6. 0. 4. 0. 2. 0. 0. 10 -6. 10 -5. 10 -4. 10 -3. 10 -2. 10 -1. 10 0.

208 views • 7 slides

Supplementary Figure 1. Suzuki et al.

BrdU. DAPI/BrdU. 24 hrs. 24 hrs. 48 hrs. 48 hrs. 72 hrs. 72 hrs. Supplementary Figure 1. Suzuki et al. A. B. Supplementary Figure 2. Suzuki et al. p. CPD. H2AX. Merge. p. (6-4) photo. H2AX. Merge. p. XRCC1. H2AX. Merge. Supplementary Figure 3. Suzuki et al. No UV. 3 min.

187 views • 8 slides

Weaver et al. supplemental Figure 1

Weaver et al. supplemental Figure 1. A BALB/c. Epitope. Immunogen. Peptide. B1. B2. B3. B4. B5. B6. B7. B8. B9. B10. B11. B12. UG37(A). KVTFEPIPIHYCAPA (53). STVQCTHGIRPVVST (62). RIKQIINMWQRVGQA (104). GIVQQQSNLLRAIEAQQHLLKLTVWGIKQLQ (136,137,138,140).

114 views • 3 slides

Supplementary Figure 1 Logan et al

IP Ab. HSF1. we. Irr. p63. HSF1 Int. I. II. III. IV. V. F/l.  Pro. 1-292. 248-393. 1-42. TAD DBD Oligo. +. +. 248-393. 1-42. 1-292.  Pro. GST. Inputs. F/l. +. -. -. Pull down. Supplementary Figure 1 Logan et al.

112 views • 4 slides

Kuhlmann et al. Suppl. Figure 1

Kuhlmann et al. Suppl. Figure 1. SALK_079574. Gabi-Kat_516A07. SRA-domain. SET-domain. At2g33290 SUVH2. Gabi-Kat_516A07. LB-p1::SUL1-p35S> RB RB <p35S-SUL1::P1-LB. pAC161. pAC161. TGAACGGCAA 1937bp. 1946bp CTGCAACTAG. SALK_048033. SRA-domain. SET-domain. At4g13460 SUVH9.

187 views • 8 slides

Figure 1 - Ma et al.

b6. b5. K79. b3 . b4. D126. b1 . a2. R58. b2 . R57. N. b6. b7. C. a3. b3. b2. R126. b1. a1. R149. R107. Figure 1 - Ma et al. Figure 2 - Ma et al. K79. C176. T81. A145. G147. R76. H83. G160. G158. Y91. Figure 3 - Ma et al. Figure 4 - Ma et al.

158 views • 6 slides

Abdelkarim M et al .. Figure 1

FXR -/- + RSG. FXR +/+ + RSG. 250 µm. 250 µm. A. Weight of BAT. 0.7. Control. 0.6. **. RSG. ***. 0.5. 0.4. Weight (g). 0.3. C. 0.2. 0.1. 0. FXR +/+. FXR -/-. B. FXR +/+ - Control. 20. FXR +/+ + RSG. 15. Adipocyte fraction (%). 10. 5. 0. FXR -/- - Control. 20.

181 views • 8 slides

Supplemental Figure 1 Narainsamy et al.

Supplemental Figure 1 Narainsamy et al. A. B. Supplemental Figure 2 Narainsamy et al. A. B. 3276. 1375. 757. 1438. Supplemental Figure 3 Narainsamy et al. B. Positive ion mode. Negative ion mode. <10. 10-25. 25-35. 35-50. >50. <10. 10-25. 25-35. 35-50. >50. CV (%).

157 views • 7 slides

Supporting Figure 1. Li et al.

A. Supporting Figure 1. Li et al. B. Supporting Figure 1. Li et al. C. Supporting Figure 1. Li et al.

111 views • 3 slides

Biajoux et al. Suppl. Figure 1

Biajoux et al. Suppl. Figure 1. CXCR4 geometric MFI in total CD19 + B cells. A. CXCR4 geometric MFI in CD19 + CD27 - B cells. CXCR4 geometric MFI in total CD19 + B cells. H = 33.08 P < 0.0001. H = 24.31 P < 0.0001. H = 4.886 P = 0.180. B. CXCR7 geometric MFI

122 views • 1 slides

Wang et al. Figure S 1.

Wang et al. Figure S 1. A. B. Type І. X 26-37 C X 9 C X 13-15 CC X 19 C X C X 19-24 C X 13-15 C X 4-9. Type III. X 28-33 C X 9 C X 14-19 CC X 9 C X C X 12 C X 6-9 C X 1-14. Type V. X 24-37 C X 14 C X 14 CC X 11-13 C X C X 24 C X 10 C X 6,10. Type IV.

184 views • 5 slides

Supplementary Figure 1 Gattolliat et al

Supplementary Figure 1 Gattolliat et al. Overall survival. Disease -free survival. High miR -487b. High miR -487b. Disease-free surviving (%). Patient surviving (%). Low miR-487b. Low miR-487b. P=0.0671. P=0.0589. Overall survival (months). Disease-Free survival (months).

100 views • 1 slides

Kiem et al., Supplemental Figure 1

Kiem et al., Supplemental Figure 1. Relative luciferase expression. control. human CCR5-741. human CCR5-1024. macaque CCR5-741. macaque CCR5-1024.

95 views • 1 slides

Fujita et al., Figure 1.

Fujita et al., Figure 1. CSLEX. NCC-ST-439. CEA. BCA225. 1.00. 1.00. 1.00. 1.00. CA15-3. 1.00. .75. Merge. .75. .75. .75. .75. sensitivity. 1.00. .50. sensitivity. sensitivity. sensitivity. .50. .50. .50. sensitivity. .50. .75. .25. .25. .25. .25. .25.

160 views • 2 slides

Supplementary figure 1 Palacios et. al

E-cadherin. Transferrin. Merge. 35 °C/ 4hrs. Supplementary figure 1 Palacios et. al. 0 4 8 12 0 4 8 12. Hours of v-Src activation. Extracellular domain epitope Cytoplasmic domain epitope. { Anti-E-cadherin. Supplementary figure 2

91 views • 2 slides

Douglas et al. figure 1

Douglas et al. figure 1.

90 views • 1 slides

More Related